Ann: Postcard to Shareholders, page-8

I just watched the IXC corporate spotlight on HC at the top of the page.

It still amazes me the current Market Cap for IXC... as an elevator pitch IXC has a drug that is known to be safe, and is approved for another indication. Has shown to work on a small phase 2 for the indication it is aiming for. Has zero competition for the market it is going to enter. Has been told what trial needs to be run in Europe for approval. And has the money to fund the required trial.

The only question mark is over US market and FDA requirements. However, the EU market will make the MC go 10 fold from here easy, so risk wise the US isn't a big deal. Also, it will only be a matter of time before they do what is needed for FDA/US.

I won't be able to tune into the presentation tomorrow, however I hope it is a good pitch to the market.

IMO, DYOR, etc